| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Lurasidone | hsa00030 | Pentose phosphate pathway | 9.38E-07 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | | Lurasidone | hsa00190 | Oxidative phosphorylation | 4.38E-04 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | | Lurasidone | hsa00240 | Pyrimidine metabolism | 4.29E-02 | 2 | P21589, P04183 | NT5E, TK1 | More | | | Lurasidone | hsa00513 | Various types of N-glycan biosynthesis | 4.96E-02 | 1 | Q9NR34 | MAN1C1 | More | | | Lurasidone | hsa00562 | Inositol phosphate metabolism | 3.69E-02 | 3 | P27987, P19174, P42338 | ITPKB, PLCG1, PIK3CB | More | | | Lurasidone | hsa00564 | Glycerophospholipid metabolism | 4.29E-02 | 2 | Q6P1A2, P23743 | MBOAT5, DGKA | More | | | Lurasidone | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | | Lurasidone | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | | Lurasidone | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.29E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | | Lurasidone | hsa00670 | One carbon pool by folate | 1.33E-02 | 2 | P04818, Q99707 | TYMS, MTR | More | | | Lurasidone | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | | Lurasidone | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | | Lurasidone | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | | Lurasidone | hsa00983 | Drug metabolism - other enzymes | 3.32E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | | Lurasidone | hsa01100 | Metabolic pathways | 4.11E-02 | 7 | P30041, P20839, P08237, Q86XP1, Q9UHK6, Q86VZ5, Q9NVH6 | PRDX6, IMPDH1, PFKM, DGKH, AMACR, SGMS1, TMLHE | More | | | Lurasidone | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | | Lurasidone | hsa01230 | Biosynthesis of amino acids | 2.26E-03 | 4 | P51854, P60891, P05089, P37837 | TKTL1, PRPS1, ARG1, TALDO1 | More | | | Lurasidone | hsa01523 | Antifolate resistance | 1.88E-03 | 4 | P41440, Q92820, P04818, P01375 | SLC19A1, GGH, TYMS, TNF | More | | | Lurasidone | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | | Lurasidone | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | | Lurasidone | hsa03040 | Spliceosome | 6.28E-03 | 6 | Q14562, O43143, O60508, Q07955, Q01130, Q13243 | DHX8, DHX15, CDC40, SFRS1, SFRS2, SFRS5 | More | | | Lurasidone | hsa04010 | MAPK signaling pathway | 1.53E-02 | 2 | Q9H2K8, Q12933 | TAOK3, TRAF2 | More | | | Lurasidone | hsa04012 | ErbB signaling pathway | 1.71E-03 | 5 | P16333, Q13191, P19174, P42338, P01106 | NCK1, CBLB, PLCG1, PIK3CB, MYC | More | | | Lurasidone | hsa04015 | Rap1 signaling pathway | 3.07E-02 | 4 | P25116, Q8TEU7, P08514, P17252 | F2R, RAPGEF6, ITGA2B, PRKCA | More | | | Lurasidone | hsa04024 | cAMP signaling pathway | 4.38E-02 | 4 | P42338, P0DP23, Q13370, Q13009 | PIK3CB, CALM1, PDE3B, TIAM1 | More | | | Lurasidone | hsa04060 | Cytokine-cytokine receptor interaction | 2.09E-02 | 8 | P14784, P14778, Q06643, Q13651, Q9HBE5, P09341, P19875, Q93038 | IL2RB, IL1R1, LTB, IL10RA, IL21R, CXCL1, CXCL2, TNFRSF25 | More | | | Lurasidone | hsa04064 | NF-kappa B signaling pathway | 1.20E-04 | 17 | P10415, Q13489, O00463, P14778, P01375, P29965, P19174, Q04759, Q9UDY8, Q16548, P06239, Q8WV28, Q13315, P24522, P09341, P19875, Q06643 | BCL2, BIRC3, TRAF5, IL1R1, TNF, CD40LG, PLCG1, PRKCQ, MALT1, BCL2A1, LCK, BLNK, ATM, GADD45A, CXCL1, CXCL2, LTB | More | | | Lurasidone | hsa04070 | Phosphatidylinositol signaling system | 4.22E-03 | 6 | P0DP23, Q14643, P42338, P23743, P27987, P17252 | CALM1, ITPR1, PIK3CB, DGKA, ITPKB, PRKCA | More | | | Lurasidone | hsa04071 | Sphingolipid signaling pathway | 1.65E-04 | 9 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, P10415, Q12933, Q02156 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2, TRAF2, PRKCE | More | | | Lurasidone | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | | Lurasidone | hsa04110 | Cell cycle | 8.83E-05 | 8 | Q9UBD5, P06493, O60566, Q14683, P30304, P33981, P42773, P01106 | ORC3, CDK1, BUB1B, SMC1A, CDC25A, TTK, CDKN2C, MYC | More | | | Lurasidone | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | | Lurasidone | hsa04140 | Autophagy - animal | 1.56E-02 | 4 | Q9Y4H2, P42338, Q9NQL2, Q04759 | IRS2, PIK3CB, RRAGD, PRKCQ | More | | | Lurasidone | hsa04144 | Endocytosis | 4.10E-02 | 3 | O75351, P62491, Q14161 | VPS4B, RAB11A, GIT2 | More | | | Lurasidone | hsa04145 | Phagosome | 1.59E-03 | 7 | Q15080, P14598, Q13509, P68371, Q13488, O60603, P13765 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, TLR2, HLA-DOB | More | | | Lurasidone | hsa04151 | PI3K-Akt signaling pathway | 4.50E-02 | 9 | P25116, P49767, Q13362, P62873, P16144, O60603, P01568, P10415, P17252 | F2R, VEGFC, PPP2R5C, GNB1, ITGB4, TLR2, IFNA21, BCL2, PRKCA | More | | | Lurasidone | hsa04213 | Longevity regulating pathway - multiple species | 1.56E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | | Lurasidone | hsa04217 | Necroptosis | 6.91E-04 | 11 | P01375, P01568, P48023, Q13489, P42224, Q14765, Q6FI13, Q99878, P10415, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, H2AC18; H2AC19, H2AC14, BCL2, CHMP2A, PPID | More | | | Lurasidone | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.31E-03 | 8 | P09493, P07550, P22694, P18848, Q13362, P0DP23, P17252, P10415 | TPM1, ADRB2, PRKACB, ATF4, PPP2R5C, CALM1, PRKCA, BCL2 | More | | | Lurasidone | hsa04330 | Notch signaling pathway | 7.49E-03 | 2 | Q92542, P49768 | NCSTN, PSEN1 | More | | | Lurasidone | hsa04360 | Axon guidance | 1.71E-02 | 4 | P20827, O95631, P42338, P23528 | EFNA1, NTN1, PIK3CB, CFL1 | More | | | Lurasidone | hsa04370 | VEGF signaling pathway | 4.05E-02 | 2 | P19174, P42338 | PLCG1, PIK3CB | More | | | Lurasidone | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | | Lurasidone | hsa04540 | Gap junction | 1.29E-02 | 4 | P17252, Q13509, P68371, Q14643 | PRKCA, TUBB3, TUBB2C, ITPR1 | More | | | Lurasidone | hsa04611 | Platelet activation | 3.39E-02 | 3 | P25116, P08514, P07359 | F2R, ITGA2B, GP1BA | More | | | Lurasidone | hsa04612 | Antigen processing and presentation | 1.19E-05 | 10 | P13765, Q14953, P26715, P26717, Q07444, Q13241, P01732, P30101, P11142, P01375 | HLA-DOB, KIR2DS5, KLRC1, KLRC2, KLRC3, KLRD1, CD8A, PDIA3, HSPA8, TNF | More | | | Lurasidone | hsa04613 | Neutrophil extracellular trap formation | 3.41E-04 | 14 | P17252, O60603, P08246, P04908, Q6FI13, Q93077, P62807, O60814, P68431, P14598, Q15080, P21462, O43315, Q16539 | PRKCA, TLR2, ELA2, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, FPR1, AQP9, MAPK14 | More | | | Lurasidone | hsa04621 | NOD-like receptor signaling pathway | 3.40E-02 | 8 | Q14643, P10599, P43490, O00463, P29728, P01375, P09341, P12838 | ITPR1, TXN, PBEF1, TRAF5, OAS2, TNF, CXCL1, DEFA4 | More | | | Lurasidone | hsa04622 | RIG-I-like receptor signaling pathway | 2.47E-02 | 1 | Q12933 | TRAF2 | More | | | Lurasidone | hsa04640 | Hematopoietic cell lineage | 2.36E-04 | 12 | P14778, P27930, P11215, P25063, P07766, P09693, P01732, P01730, P06127, P09564, P13765, P01375 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD3G, CD8A, CD4, CD5, CD7, HLA-DOB, TNF | More | | | Lurasidone | hsa04650 | Natural killer cell mediated cytotoxicity | 5.56E-09 | 13 | P19174, P01375, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, P26717, Q07444, Q14953, P26715 | PLCG1, TNF, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, KLRC2, KLRC3, KIR2DS5, KLRC1 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P24723 | PRKCH | Protein kinase C eta type | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.767 | | Q04759 | PRKCQ | Protein kinase C theta type | P01375 | TNF | Tumor necrosis factor | -0.725 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | | P24723 | PRKCH | Protein kinase C eta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.912 | | Q04759 | PRKCQ | Protein kinase C theta type | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.855 | | P24723 | PRKCH | Protein kinase C eta type | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.835 | | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | | P24723 | PRKCH | Protein kinase C eta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.939 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | | P24723 | PRKCH | Protein kinase C eta type | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.79 | | Q04759 | PRKCQ | Protein kinase C theta type | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.849 | | P24723 | PRKCH | Protein kinase C eta type | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.768 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | | Q04759 | PRKCQ | Protein kinase C theta type | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.918 | | P24723 | PRKCH | Protein kinase C eta type | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.822 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | | P24723 | PRKCH | Protein kinase C eta type | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.828 | | Q04759 | PRKCQ | Protein kinase C theta type | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.803 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | | P24723 | PRKCH | Protein kinase C eta type | Q07444 | KLRC3 | NKG2-E type II integral membrane protein | 0.723 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | | Q04759 | PRKCQ | Protein kinase C theta type | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.803 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 |
| | Lurasidone | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | | | Lurasidone | hsa04658 | Th1 and Th2 cell differentiation | 1.04E-08 | 12 | Q04759, P07766, P20963, P09693, P19174, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, PLCG1, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | | Lurasidone | hsa04659 | Th17 cell differentiation | 1.97E-08 | 15 | Q04759, P19174, P06239, P42224, P14784, P13765, P14778, Q9HBE5, P40189, Q9UL17, P23771, P08238, P07766, P09693, P20963 | PRKCQ, PLCG1, LCK, STAT1, IL2RB, HLA-DOB, IL1R1, IL21R, IL6ST, TBX21, GATA3, HSP90AB1, CD3E, CD3G, CD247 | More | | | Lurasidone | hsa04660 | T cell receptor signaling pathway | 8.92E-07 | 12 | P01375, Q04759, P42338, O95267, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239 | TNF, PRKCQ, PIK3CB, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK | More | | | Lurasidone | hsa04662 | B cell receptor signaling pathway | 2.11E-02 | 4 | P42338, P60033, P21854, Q8N149 | PIK3CB, CD81, CD72, LILRA2 | More | | | Lurasidone | hsa04666 | Fc gamma R-mediated phagocytosis | 3.08E-02 | 3 | P42338, P23528, P14598 | PIK3CB, CFL1, NCF1 | More | | | Lurasidone | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | | Lurasidone | hsa04672 | Intestinal immune network for IgA production | 1.06E-04 | 3 | P29965, P10747, P13765 | CD40LG, CD28, HLA-DOB | More | | | Lurasidone | hsa04713 | Circadian entrainment | 2.60E-02 | 4 | P0DP23, P17252, P62873, Q14643 | CALM1, PRKCA, GNB1, ITPR1 | More | | | Lurasidone | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | | Lurasidone | hsa04720 | Long-term potentiation | 3.89E-02 | 3 | P17252, P0DP23, Q14643 | PRKCA, CALM1, ITPR1 | More | | | Lurasidone | hsa04722 | Neurotrophin signaling pathway | 1.98E-03 | 5 | Q05655, P49841, O43524, P48023, P52566 | PRKCD, GSK3B, FOXO3, FASLG, ARHGDIB | More | | | Lurasidone | hsa04723 | Retrograde endocannabinoid signaling | 1.88E-02 | 4 | Q14643, P17252, P62873, Q16718 | ITPR1, PRKCA, GNB1, NDUFA5 | More | | | Lurasidone | hsa04725 | Cholinergic synapse | 1.88E-02 | 4 | Q14643, P17252, P62873, P10415 | ITPR1, PRKCA, GNB1, BCL2 | More | | | Lurasidone | hsa04728 | Dopaminergic synapse | 3.55E-02 | 5 | Q14643, P17252, P62873, Q13362, P0DP23 | ITPR1, PRKCA, GNB1, PPP2R5C, CALM1 | More | | | Lurasidone | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | | Lurasidone | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | | Lurasidone | hsa04744 | Phototransduction | 1.02E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | | Lurasidone | hsa04750 | Inflammatory mediator regulation of TRP channels | 2.19E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | | Lurasidone | hsa04912 | GnRH signaling pathway | 3.89E-02 | 3 | P17252, Q14643, P0DP23 | PRKCA, ITPR1, CALM1 | More | | | Lurasidone | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | | Lurasidone | hsa04914 | Progesterone-mediated oocyte maturation | 3.92E-02 | 3 | P42338, Q13370, P08238 | PIK3CB, PDE3B, HSP90AB1 | More | | | Lurasidone | hsa04918 | Thyroid hormone synthesis | 3.16E-02 | 2 | P17252, P27824 | PRKCA, CANX | More | | | Lurasidone | hsa04919 | Thyroid hormone signaling pathway | 3.71E-02 | 2 | P26678, P08237 | PLN, PFKM | More | | | Lurasidone | hsa04922 | Glucagon signaling pathway | 3.47E-02 | 4 | Q12778, Q13370, P0DP23, Q14643 | FOXO1, PDE3B, CALM1, ITPR1 | More | | | Lurasidone | hsa04924 | Renin secretion | 6.30E-05 | 5 | P22694, P07550, Q14643, Q13370, P0DP23 | PRKACB, ADRB2, ITPR1, PDE3B, CALM1 | More | | | Lurasidone | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | | Lurasidone | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | | Lurasidone | hsa04930 | Type II diabetes mellitus | 9.83E-04 | 2 | Q05655, Q02156 | PRKCD, PRKCE | More | | | Lurasidone | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | | Lurasidone | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.27E-02 | 5 | P42224, P10415, Q12778, P49767, P17252 | STAT1, BCL2, FOXO1, VEGFC, PRKCA | More | | | Lurasidone | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Lurasidone | hsa04962 | Vasopressin-regulated water reabsorption | 1.80E-02 | 2 | P62491, P46459 | RAB11A, NSF | More | | | Lurasidone | hsa04966 | Collecting duct acid secretion | 2.86E-02 | 2 | Q13488, Q9Y666 | TCIRG1, SLC12A7 | More | | | Lurasidone | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | | Lurasidone | hsa04974 | Protein digestion and absorption | 2.47E-02 | 1 | Q7Z2H8 | SLC36A1 | More | | | Lurasidone | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | | Lurasidone | hsa05010 | Alzheimer disease | 3.55E-02 | 7 | Q16718, O14521, Q14643, P0DP23, Q13509, P68371, Q08752 | NDUFA5, SDHD, ITPR1, CALM1, TUBB3, TUBB2C, PPID | More | | | Lurasidone | hsa05012 | Parkinson disease | 2.25E-02 | 6 | Q16718, O14521, Q14643, P0DP23, Q13509, P68371 | NDUFA5, SDHD, ITPR1, CALM1, TUBB3, TUBB2C | More | | | Lurasidone | hsa05020 | Prion disease | 1.31E-03 | 9 | Q16718, O14521, Q14643, Q13509, P68371, P49841, P14598, Q15080, Q16539 | NDUFA5, SDHD, ITPR1, TUBB3, TUBB2C, GSK3B, NCF1, NCF4, MAPK14 | More | | | Lurasidone | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.00E-04 | 12 | Q14643, Q13509, P68371, P49841, P10415, Q16718, O14521, Q13561, P17252, Q16539, Q08752, P0DP23 | ITPR1, TUBB3, TUBB2C, GSK3B, BCL2, NDUFA5, SDHD, DCTN2, PRKCA, MAPK14, PPID, CALM1 | More | | | Lurasidone | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | | Lurasidone | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Lurasidone | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 4.95E-02 | 3 | P09341, P19875, P19174 | CXCL1, CXCL2, PLCG1 | More | | | Lurasidone | hsa05131 | Shigellosis | 4.98E-04 | 12 | Q12933, P68431, Q05655, Q02156, Q9UDY8, Q14247, Q14643, Q12778, Q13315, P10415, Q08752, P07737 | TRAF2, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, PRKCD, PRKCE, MALT1, CTTN, ITPR1, FOXO1, ATM, BCL2, PPID, PFN1 | More | | | Lurasidone | hsa05132 | Salmonella infection | 6.68E-03 | 10 | Q9UJU2, P84095, Q13489, P10415, P07737, O60603, Q9BQS8, Q13561, Q13509, P68371 | LEF1, RHOG, BIRC3, BCL2, PFN1, TLR2, FYCO1, DCTN2, TUBB3, TUBB2C | More | | | Lurasidone | hsa05134 | Legionellosis | 4.88E-03 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | | Lurasidone | hsa05135 | Yersinia infection | 4.39E-02 | 4 | P06239, P19174, P42338, P01732 | LCK, PLCG1, PIK3CB, CD8A | More | | | Lurasidone | hsa05140 | Leishmaniasis | 2.17E-03 | 6 | P14598, P42224, P13765, O60603, P29350, Q15080 | NCF1, STAT1, HLA-DOB, TLR2, PTPN6, NCF4 | More | | | Lurasidone | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | | Lurasidone | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | | | Lurasidone | hsa05145 | Toxoplasmosis | 1.11E-02 | 6 | P10415, Q13489, P42224, P13765, O60603, P29965 | BCL2, BIRC3, STAT1, HLA-DOB, TLR2, CD40LG | More | | | Lurasidone | hsa05146 | Amoebiasis | 6.73E-08 | 12 | P09341, P19875, P14778, P27930, P01375, P42338, P11215, P05089, P30679, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | | Lurasidone | hsa05152 | Tuberculosis | 7.93E-04 | 8 | Q13488, P0DP23, P42224, O60603, P10415, P13765, P01568, Q9UDY8 | TCIRG1, CALM1, STAT1, TLR2, BCL2, HLA-DOB, IFNA21, MALT1 | More | | | Lurasidone | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | | Lurasidone | hsa05165 | Human papillomavirus infection | 3.10E-02 | 8 | P16144, Q05086, P01568, P42224, Q13488, Q13362, Q12778, Q13315 | ITGB4, UBE3A, IFNA21, STAT1, TCIRG1, PPP2R5C, FOXO1, ATM | More | | | Lurasidone | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.73E-02 | 6 | P01568, P42224, P62873, Q14643, P0DP23, Q9UJU2 | IFNA21, STAT1, GNB1, ITPR1, CALM1, LEF1 | More | | | Lurasidone | hsa05168 | Herpes simplex virus 1 infection | 1.15E-02 | 8 | P42224, Q07955, Q01130, Q13243, P42338, Q13398, Q03923, Q9UDV6 | STAT1, SFRS1, SFRS2, SFRS5, PIK3CB, ZNF211, ZNF85, ZNF212 | More | | | Lurasidone | hsa05169 | Epstein-Barr virus infection | 3.13E-02 | 9 | P13765, Q13547, O00463, P24522, P01375, P29728, P07766, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, GADD45A, TNF, OAS2, CD3E, CD3G, CD247 | More | | | Lurasidone | hsa05170 | Human immunodeficiency virus 1 infection | 4.67E-03 | 9 | P62873, P0DP23, P17252, Q14643, P01568, O60603, Q13315, P10415, Q9Y6Q5 | GNB1, CALM1, PRKCA, ITPR1, IFNA21, TLR2, ATM, BCL2, AP1M2 | More | | | Lurasidone | hsa05200 | Pathways in cancer | 6.34E-03 | 18 | P42338, P08238, P42224, Q9UJU2, P17252, P43246, P14923, P10415, Q13489, P49767, Q12778, P25116, P62873, O75293, P0DP23, P01568, P14784, P40189 | PIK3CB, HSP90AB1, STAT1, LEF1, PRKCA, MSH2, JUP, BCL2, BIRC3, VEGFC, FOXO1, F2R, GNB1, GADD45B, CALM1, IFNA21, IL2RB, IL6ST | More | | | Lurasidone | hsa05202 | Transcriptional misregulation in cancer | 3.92E-02 | 10 | P14780, P27930, Q15744, Q16548, P05164, P12838, P08246, Q9C0K0, Q13547, P24522 | MMP9, IL1R2, CEBPE, BCL2A1, MPO, DEFA4, ELA2, BCL11B, HDAC1, GADD45A | More | | | Lurasidone | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | | Lurasidone | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | | Lurasidone | hsa05205 | Proteoglycans in cancer | 4.46E-03 | 9 | Q12955, Q14247, P14780, P17252, P01375, P23588, Q13635, P22694, P08962 | ANK3, CTTN, MMP9, PRKCA, TNF, EIF4B, PTCH1, PRKACB, CD63 | More | | | Lurasidone | hsa05212 | Pancreatic cancer | 1.72E-02 | 3 | P42338, P42224, O75293 | PIK3CB, STAT1, GADD45B | More | | | Lurasidone | hsa05214 | Glioma | 1.72E-02 | 3 | P0DP23, P42338, O75293 | CALM1, PIK3CB, GADD45B | More | | | Lurasidone | hsa05221 | Acute myeloid leukemia | 4.95E-02 | 3 | P42338, Q15744, P11215 | PIK3CB, CEBPE, ITGAM | More | | | Lurasidone | hsa05231 | Choline metabolism in cancer | 2.60E-02 | 3 | Q9Y259, P19174, P49619 | CHKB, PLCG1, DGKG | More | | | Lurasidone | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.34E-04 | 8 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, Q04759 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, PRKCQ | More | | | Lurasidone | hsa05310 | Asthma | 2.59E-04 | 4 | P13765, P29965, P12724, P01375 | HLA-DOB, CD40LG, RNASE3, TNF | More | | | Lurasidone | hsa05320 | Autoimmune thyroid disease | 1.05E-04 | 4 | P13765, P29965, P01568, P10747 | HLA-DOB, CD40LG, IFNA21, CD28 | More | | | Lurasidone | hsa05321 | Inflammatory bowel disease | 1.83E-05 | 6 | P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | | | Lurasidone | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 10 | P08246, P09871, P10747, P13765, P29965, Q6FI13, Q93077, P62807, O60814, P68431 | ELA2, C1S, CD28, HLA-DOB, CD40LG, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Lurasidone | hsa05323 | Rheumatoid arthritis | 1.59E-03 | 7 | Q06643, P13765, Q13488, P10747, P09341, P19875, O60603 | LTB, HLA-DOB, TCIRG1, CD28, CXCL1, CXCL2, TLR2 | More | | | Lurasidone | hsa05330 | Allograft rejection | 7.91E-05 | 5 | P13765, P29965, P48023, P10747, P01375 | HLA-DOB, CD40LG, FASLG, CD28, TNF | More | | | Lurasidone | hsa05332 | Graft-versus-host disease | 1.75E-05 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | | | Lurasidone | hsa05340 | Primary immunodeficiency | 4.95E-02 | 3 | P01732, P07766, P06239 | CD8A, CD3E, LCK | More | | | Lurasidone | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 1.82E-02 | 3 | P14923, P08514, Q9UJU2 | JUP, ITGA2B, LEF1 | More | | | Lurasidone | hsa05415 | Diabetic cardiomyopathy | 1.58E-03 | 7 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B | More | | | Lurasidone | hsa05416 | Viral myocarditis | 2.61E-03 | 3 | P13765, P29965, P10747 | HLA-DOB, CD40LG, CD28 | More | | | Lurasidone | hsa05418 | Fluid shear stress and atherosclerosis | 3.73E-02 | 4 | P42338, P14598, P0DP23, P08238 | PIK3CB, NCF1, CALM1, HSP90AB1 | More | |
|
